I would still vote No to RS
---------
1:10- 20 -30 RS? This is really a reverse merger on the making, the 2 companies are just calling it something else. (NantCell is private, no disclosures needed, you got to love that)
Pre split price will drop to: $ .35 (this drop is the anticipated panic selling due to RS news simering over the weekend. Preliminary proxy because they need to know the pre split final lowest possible share price.
Bait and hook. This price will bounce to .70+
Post split share price will be: $ 6 to 7
Mr Soon is already allowed to buy 3m shares at $1.10 pre or post split price.
The share price after split will be $6+, Mr. Soon just got a heavy discount per share when he exercises his buying power at $1.10) his purchase will give him mayority ownership on CYTR and leaves 2.5m OS, and he made $18m out of $3m
from buying at $1.10 a share. That is a $2m profit from his $16m investment. The stock should but not necesarily sky rocket,
It Figures
--------------
550k shares left post split already owned from original 11million share split.
3m share purcjase allowance at $1.10
= 3.5m total post split owned by Mr. Soon costed him $16million but he now owns
51+% of CYTR instead of 6.67 % from the previous engament licensing deal.
5.5 (post split OS) - 3.5m (Mr. Soon) = 2.5m left to buy
MC = 14m 20m, 30m?
--------------
The lower the share price goes presplit the more Mr Soon will own on CYTR post split, he already bought the company as far as we should all know. (Very controversial)
Thats why 325mil in double digit and other royalties were granted to CYTR on the licensing deal (this is the sales pitch)
" CytRx is entitled to receive up to another USD 343 million in milestone payments related to regulatory approvals and commercial milestones for aldoxorubicin as well as will receive increasing double-digit royalties for sales of aldoxorubicin for soft tissue sarcomas and mid to high single digit royalties for all other indications. NantCell will be responsible for all future development, manufacturing and commercialization expenses. Concurrently, CytRx will make a payment of USD 5 million to the lender upon the closing of the exclusive global license and strategic investment for aldoxorubicin "
This theory has positives:
New management
Lower OS
Very flipping genius.
Ill be darn
That math is confusing.
Wise
